all report title image

GLOBAL CHOLERA VACCINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Cholera Vaccines Market, By Product Type (Vaxchora, Dukoral, ShanChol, Euvichol-Plus/Euvichol, Others), By Vaccine Type (Killed Whole-cell and Recombinant Cholera Toxin B Vaccine, Killed Whole-cell Only Vaccines, Live Attenuated Oral Cholera, Vaccine), By Patient Type (Pediatric, Adults), By Distribution Channel (Public, Private), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published In : Feb 2024
  • Code : CMI6646
  • Pages :180
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

The global cholera vaccines market was valued US$ 82.5 Mn in 2023 and is expected to reach US$ 204.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12% from 2024 to 2031. 

Cholera is spread through contaminated food or water. It is not usually spread directly from person to person, but it can be spread through contact with the feces of an infected person. Cholera causes severe diarrhea and vomiting. If it isn’t treated quickly, it can lead to dehydration and even death.

Global Cholera Vaccines Market - Regional Insights

  • North America is expected to be the largest market for cholera vaccines during the forecast period, accounting for over 37.1% of the market share in 2023. North America is anticipated to dominate the global cholera vaccines market during the forecast period due to strong public healthcare support and high awareness levels about cholera vaccination in the region.
  • Europe market is expected to be the second-largest market for cholera vaccines market accounting for over 20.6% of the market share in 2024. Europe is likely to witness the fastest gains and emerge as the most lucrative region towards the latter half of the forecast period. This can be attributed to increasing adoption of inorganic growth strategies by key market players.

Figure 1. Global Cholera Vaccines Market Share (%), By Region, 2023

GLOBAL CHOLERA VACCINES MARKET

To learn more about this report, Request sample copy

Analyst View:

The global cholera vaccines market is expected to witness steady growth over the forecast period. The increasing prevalence of cholera cases worldwide will drive the demand for effective vaccines. Developing nations that have inadequate sanitation and water supplies remain highly susceptible to cholera outbreaks. As governments and NGOs work to improve public health infrastructure in these regions, vaccination programs will play a crucial preventive role against the spread of the disease. Meanwhile, political instability and conflict situations can negatively impact vaccination drives in certain parts of the world. Maintaining adequate vaccine supplies and a cold chain for storage and distribution also poses challenges, especially in remote areas.

Global Cholera Vaccines Market- Drivers

  • Increasing Vaccination Campaigns: Increasing vaccination campaigns by healthcare organizations such as the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) are expected to drive the global cholera vaccines market over the forecast period. For instance, on March 8, 2023, the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF), a humanitarian aid organization, in coordination with health authorities, the Syria Immunization Group (SIG), and the Global Alliance for Vaccines (GAVI), kicked off a cholera vaccination campaign in earthquake-hit areas of northwest Syria. During the campaign, 1.7 million doses of cholera vaccine will be used to protect Syrians above one year of age, especially those living in the areas most severely impacted by the earthquake and at highest risk of cholera, including Sarmada, Maaret Tamsrin, Dana, and Atmeh districts in Idleb, and in A’zaz district in northern Aleppo.
  • Increasing Fundings and Investments: Increasing adoption of inorganic growth strategies such as fundings and investments is expected to drive the global cholera vaccines market. For instance, In July 2022, the U.S. Agency for International Development (USAID) provided nearly US$ 1,180 million surge in humanitarian assistance that allowed USAID partners to provide critical aid for millions of people across the region. This funding includes urgent health support and investigations to identify potential diseases, such as cholera. As the risk for infectious disease increases when water sources are contaminated, USAID is providing water, sanitation, and hygiene support in drought-affected areas to include safe, potable water through water trucking, repaired water boreholes, community wells, and distribution systems.

Global Cholera Vaccines Market- Opportunities

  • Increasing Educational Training Programmes: Increasing educational training programs regarding cholera vaccine manufacturing is expected to drive market growth over the forecast period. According to the data provided by the International Vaccine Institute (IVI), in December 2022, the International Vaccine Institute (IVI) conducted on-site training and consultation for Afrigen Biologics & Vaccines (Afrigen) in South Africa to help strengthen the company’s manufacturing capacity as part of the GLOBAL TRAINING HUB FOR BIO MANUFACTURING (GTH-B) PROGRAM and was funded by the Korean Ministry Of Health And Welfare. The training led by a team of senior IVI scientists provided education on overall production, including vaccine technology transfer, manufacturing-related safety, quality management system, and good laboratory practice (GLP).
  • Potential for Combination Vaccines: Potential for combination vaccines could provide a great opportunity in the global cholera vaccines market. As per the World Health Organization (WHO), combination vaccines help reduce the number of injections given to a child and may improve vaccination coverage rates. This approach carries significant benefits, especially in low and middle-income countries where immunization resources are often constrained. Combination vaccines targeting cholera along with other endemic diseases in vulnerable regions can help improve both access and uptake of immunization in integrated vaccination programs.

Global Cholera Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2023: US$ 82.5 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2024 to 2031 CAGR: 12% 2031 Value Projection: US$ 204.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa 
Segments covered:
  • By Product Type: Vaxchora, Dukoral, ShanChol, Euvichol-Plus/Euvichol, Others (Late Phase Vaccines, etc.)
  • By Vaccine Type: Killed Whole-cell and Recombinant Cholera Toxin B Vaccine, Killed Whole-cell Only Vaccines, Live Attenuated Oral Cholera, Vaccine
  • By Patient Type: Pediatric, Adults
  • By Distribution Channel: Public, Private
Companies covered:

Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD.

Growth Drivers:
  • Increasing Vaccination Campaigns
  • Increasing Fundings and Investments
Restraints & Challenges:
  • Supply Shortage of Cholera Vaccine

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Cholera Vaccines Market – Trends

  • Growth in research funding and grants: Increasing adoption of inorganic growth strategies such as funding and grants is expected to drive the global cholera vaccines market over the forecast period. For instance, on January 25, 2023, the International Federation of Red Cross’s (IFRC) Disaster Response Emergency Fund approved a grant of nearly 500,000 Swiss francs to help the Mozambique Red Cross address a cholera outbreak that is affecting five provinces. The Red Cross is part of Mozambique’s national disaster management structure and the inter-agency humanitarian country team.

Global Cholera Vaccines Market - Restraints

  • Supply Shortage of Cholera Vaccine: The increasing cases of cholera infectious disease can increase the demand for cholera vaccine, which leads to the supply shortage of cholera vaccine and can hamper market growth over the forecast period.
  • The increasing cases of cholera infectious diseases in Southern African countries such as Mozambique, Zimbabwe, and others can lead to high demand for cholera vaccines in the Southern African region, which was responsible for the shortage of cholera vaccines. Thus supply shortage of cholera vaccine can hamper the growth of market over the forecast period. For instance, according to data provided by Africa’s Public Health Agency, on February 3, 2023, Southern African countries with deadly cholera outbreaks had no immediate access to cholera vaccines, which leads to an increased in cholera infection. Therefore, the countries temporarily switched to use a single dose of cholera vaccine instead of double dose because of the supply shortage as outbreak of water-borne diseases such as cholera. Thus, the temporary supply shortage of cholera vaccine can hamper market growth over the forecast period.
  • Counterbalance: Thus, key market players should focused on adoption of inorganic strategies such as supply and distribution agreements to meet the increasing demand for cholera vaccines

Figure 2. Global Cholera Vaccines Market Share (%), By Product Type, 2023

GLOBAL CHOLERA VACCINES MARKET

To learn more about this report, Request sample copy

Global Cholera Vaccines Market - Recent Developments

Vaccination Campaigns

  • On January 29, 2024, the Government of Zimbabwe launched a vaccination campaign against cholera in collaboration with UNICEF and the World Health Organization (WHO). The first cholera vaccines were administered by the Health and Child Care Honorable Minister, Dr Douglas Mombeshora during an event in Kuwadzana.
  • On December 13, 2023, health authorities in the Congo and international health partners launched a vaccination campaign against cholera that is targeting more than 5 million residents in four provinces. The launch of this mass campaign against cholera with the use of the oral vaccine in the targeted provinces will help protect a significant number of people in vulnerable situations and is also crucial to prevent the further spread of the disease to other fragile and exposed areas.

Fundings

  • In July 2022, the U.S. Agency for International Development (USAID) provided nearly US$ 1,180 million surge in humanitarian assistance that allowed USAID partners to provide critical aid for millions of people across the region. This funding includes urgent health support and investigations to identify potential diseases, such as cholera. As the risk for infectious disease increases when water sources are contaminated, USAID is providing water, sanitation, and hygiene support in drought-affected areas to include safe, potable water through water trucking, repaired water boreholes, community wells, and distribution systems.

Partnership and Collaboration

  • On May 16, 2023, Techinvention, a biotechnology company, announced a partnership with EUBIOLOGICS CO., LTD., a pharmaceutical company, to launch Euvichol-Plus, the oral cholera vaccine, in a low-density polyethylene (LDPE) unidose pack in India
  • In November 2022, co.za., South Africa-based bio-pharmaceutical company announced a licensing and technology transfer collaboration agreement with the International Vaccine Institute (IVI), a non-profit international organization headquartered in South Korea, for the manufacturing of an oral cholera vaccine (OCV) to reduce the critical shortage of vaccines needed to prevent cholera globally

Top Companies in Global Cholera Vaccines Market

  • Sanofi
  • co.za.
  • EMERGENT
  • Celldex Therapeutics
  • Valneva SE
  • Hilleman Laboratories
  • Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital)
  • PaxVax, Inc.
  • Astellas Pharma Inc.
  • EUBIOLOGICS CO., LTD.

Definition: Cholera is an infectious disease caused by the bacterium Vibrio cholerae. It is typically spread through contaminated water and can cause severe diarrhea and dehydration, potentially leading to death if untreated. A vaccine for cholera can provide protection against this disease.

Share

About Author

Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Global Cholera Vaccines Market size is estimated to be valued at USD 82.5 million in 2024 and is expected to reach USD 204.6 million in 2031.

Supply shortages of cholera vaccines are the key factor hampering growth of the global cholera vaccines market.

Increasing vaccination campaigns and increasing fundings and investments are the major factors driving the global cholera vaccines market.

Dukoral segment is the leading product type segment in the global cholera vaccines market.

The major players operating in the global cholera vaccines market are Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD.

North America leads the global cholera vaccines market.

The CAGR of the global cholera vaccines market is 12%.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.